The Royal College of Pathologists of Australasia Quality Assurance Program: Immunohistochemistry Breast Marker Audit Overview 2005-2015

摘要

This audit consisted of a questionnaire and analysis designed to assist participants (pathologists and registrars) in assessing the quality of estrogen (ER), progesterone (PR), and HER2 receptors including HER2 Bright Field In-Situ Hybridization (BRISH). BRISH testing was performed using either a single probe (ISH) or a dual probe (ISH) method [ie, Dual ISH (DISH) or Silver ISH (SISH)]; whereas, data entry responses required for the assessment with the single probe are expressed as the HER2 BRISH mean cell count, HER2 ISH status, for example, non-amplified diploid (NAD), non-amplified polysomy (NAP), equivocal, low amplification (LA), or high amplification (HA), whereas the results with the dual probe are expressed as the HER2 gene mean count per cell, Chromosome (CEP) 17 count per cell, HER2/CEP17 ratio (ratio of HER2 signal to chromosome 17 centro-meric enumeration probe (CEP 17) signal) and HER2/ CEP17 ISH status, for example amplified (A) or non-amplified (NA).